首页 > 最新文献

American Journal of Medical Genetics Part C: Seminars in Medical Genetics最新文献

英文 中文
The Impact of Karyotype on Congenital Heart Diseases in Turner Syndrome: A Systematic Review and Meta-Analysis 核型对特纳综合征先天性心脏病的影响:系统回顾和荟萃分析。
IF 4.4 3区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-06-25 DOI: 10.1002/ajmg.c.32146
Francisco Álvarez-Nava, Melissa L. Crenshaw, Ivonne Bedei, Marisol Soto, Andréa T. Maciel-Guerra, Anne Skakkebæk

It is evident that Turner syndrome (TS) impacts almost all developmental stages of the fetal heart with congenital heart disease (CHD) being seen in 23%–50% of individuals. Although the spectrum of CHDs in TS is well-established, with left-sided lesions predominating, the influence of specific karyotypes on the prevalence and types of CHDs remains incompletely understood. The primary objective of this systematic review/meta-analysis was to quantitatively synthesize the existing evidence on the association between specific karyotypes in TS and the risk of various CHDs. A systematic literature search was conducted through December 2023 to identify studies reporting the prevalence of CHDs in relation to TS karyotype. The quality of the individual studies was assessed using the Joanna Briggs Institute critical appraisal tools for systematic reviews. The overall estimates were pooled using both fixed- and random-effects models. Sensitivity and subgroup analysis were performed. Twenty-five studies were included in the analysis. TS individuals with a 45,X karyotype showed a significantly higher likelihood of bicuspid aortic valve (BAV) (pooled OR, 3.14 [95% CI: 2.49–3.94]), aortic coarctation (CoA) (pooled OR, 4.16 [95% CI: 2.74–6.31]), and partial anomalous pulmonary venous return (PAPVR) (pooled OR, 4.86 [2.31–10.2]) compared with TS individuals with a non-45,X karyotype. In addition, TS individuals with a 45,X karyotype also showed a significantly higher likelihood of BAV (pooled OR, 2.72 [95% CI: 1.62–4.56]) when compared with TS individuals with 45,X/46,XX mosaicism. TS individuals with a 45,X karyotype showed a significantly higher risk of BAV (pooled OR, 2.13 [95% CI: 1.42–3.21]) and CoA (pooled OR, 4.52 [95% CI: 1.58–13.0]) when compared with TS individuals with an isochromosome Xq. A significantly higher likelihood of BAV was also found in 45,X compared to other karyotypes (e.g., 45,X/46,XY and TS karyotypes with ring X chromosome). Some heterogeneity was evident, but publication was low. This meta-analysis confirms a strong association between the 45,X karyotype and increased prevalence of BAV, CoA, and PAPVR in TS. While 45,X/46,XX mosaicism and karyotypes with an isochromosome Xq mitigate risk, the findings emphasize the need for large-scale studies to refine risk assessment and management strategies.

很明显,特纳综合征(TS)影响胎儿心脏的几乎所有发育阶段,23%-50%的人患有先天性心脏病(CHD)。虽然TS患者的冠心病谱系已经确定,以左侧病变为主,但特定核型对冠心病患病率和类型的影响仍不完全清楚。本系统综述/荟萃分析的主要目的是定量综合有关TS特定核型与各种冠心病风险之间关系的现有证据。到2023年12月,进行了系统的文献检索,以确定报告冠心病患病率与TS核型相关的研究。使用乔安娜布里格斯研究所用于系统评价的关键评估工具来评估个体研究的质量。总体估计是使用固定效应和随机效应模型汇总的。进行敏感性和亚组分析。25项研究被纳入分析。与非45,X核型的TS个体相比,45,X核型的TS个体出现二尖瓣主动脉瓣(BAV)(合并OR, 3.14 [95% CI: 2.49-3.94])、主动脉缩窄(CoA)(合并OR, 4.16 [95% CI: 2.74-6.31])和部分肺静脉异常回流(PAPVR)(合并OR, 4.86[2.31-10.2])的可能性显著更高。此外,与具有45,X/46,XX嵌合型的TS个体相比,具有45,X核型的TS个体也显示出显著更高的BAV可能性(合并OR为2.72 [95% CI: 1.62-4.56])。与具有同染色体Xq的TS个体相比,核型为45x的TS个体发生BAV(合并OR, 2.13 [95% CI: 1.42-3.21])和CoA(合并OR, 4.52 [95% CI: 1.58-13.0])的风险明显更高。与其他核型(例如,45、X/46、XY和TS核型与环状X染色体)相比,45、X中也发现了明显更高的BAV可能性。有明显的异质性,但发表较少。该荟萃分析证实了45、X核型与TS中BAV、CoA和PAPVR患病率增加之间的密切关联。虽然45、X/46、XX嵌合体和具有Xq同工染色体的核型可降低风险,但研究结果强调需要大规模研究来完善风险评估和管理策略。
{"title":"The Impact of Karyotype on Congenital Heart Diseases in Turner Syndrome: A Systematic Review and Meta-Analysis","authors":"Francisco Álvarez-Nava,&nbsp;Melissa L. Crenshaw,&nbsp;Ivonne Bedei,&nbsp;Marisol Soto,&nbsp;Andréa T. Maciel-Guerra,&nbsp;Anne Skakkebæk","doi":"10.1002/ajmg.c.32146","DOIUrl":"10.1002/ajmg.c.32146","url":null,"abstract":"<p>It is evident that Turner syndrome (TS) impacts almost all developmental stages of the fetal heart with congenital heart disease (CHD) being seen in 23%–50% of individuals. Although the spectrum of CHDs in TS is well-established, with left-sided lesions predominating, the influence of specific karyotypes on the prevalence and types of CHDs remains incompletely understood. The primary objective of this systematic review/meta-analysis was to quantitatively synthesize the existing evidence on the association between specific karyotypes in TS and the risk of various CHDs. A systematic literature search was conducted through December 2023 to identify studies reporting the prevalence of CHDs in relation to TS karyotype. The quality of the individual studies was assessed using the Joanna Briggs Institute critical appraisal tools for systematic reviews. The overall estimates were pooled using both fixed- and random-effects models. Sensitivity and subgroup analysis were performed. Twenty-five studies were included in the analysis. TS individuals with a 45,X karyotype showed a significantly higher likelihood of bicuspid aortic valve (BAV) (pooled OR, 3.14 [95% CI: 2.49–3.94]), aortic coarctation (CoA) (pooled OR, 4.16 [95% CI: 2.74–6.31]), and partial anomalous pulmonary venous return (PAPVR) (pooled OR, 4.86 [2.31–10.2]) compared with TS individuals with a non-45,X karyotype. In addition, TS individuals with a 45,X karyotype also showed a significantly higher likelihood of BAV (pooled OR, 2.72 [95% CI: 1.62–4.56]) when compared with TS individuals with 45,X/46,XX mosaicism. TS individuals with a 45,X karyotype showed a significantly higher risk of BAV (pooled OR, 2.13 [95% CI: 1.42–3.21]) and CoA (pooled OR, 4.52 [95% CI: 1.58–13.0]) when compared with TS individuals with an isochromosome Xq. A significantly higher likelihood of BAV was also found in 45,X compared to other karyotypes (e.g., 45,X/46,XY and TS karyotypes with ring X chromosome). Some heterogeneity was evident, but publication was low. This meta-analysis confirms a strong association between the 45,X karyotype and increased prevalence of BAV, CoA, and PAPVR in TS. While 45,X/46,XX mosaicism and karyotypes with an isochromosome Xq mitigate risk, the findings emphasize the need for large-scale studies to refine risk assessment and management strategies.</p>","PeriodicalId":7445,"journal":{"name":"American Journal of Medical Genetics Part C: Seminars in Medical Genetics","volume":"199 2","pages":"93-106"},"PeriodicalIF":4.4,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajmg.c.32146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research Review of Myhre Syndrome. Myhre综合征的研究综述。
IF 2.8 3区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-06-06 DOI: 10.1002/ajmg.c.32145
Maggie R Brand, Ryan Monsberger, Robert J Hopkin, Angela E Lin

This research review of Myhre syndrome is a summary of published articles which provide a valuable resource for readers, researchers, and future authors. It traces the evolution of the Laryngotracheal-Arthropathy-Prognathism-Short Stature (LAPS) syndrome to the current eponym of Myhre syndrome. These allelic disorders are caused by pathogenic variants in SMAD4. After the initial report over 40 years ago, the steady publication of case reports and small series was accelerated following the discovery of the pathogenic variants in SMAD4. The articles in this review include numerous case reports and small series, reports about basic science, the discovery of the causative gene, the emergence of the natural history in larger studies, and articles about specific features, especially the cardiovascular system and airways. We hope this analysis provides a foundation for future research that may extend symptom-based treatment to genetic-based therapy.

这篇关于Myhre综合征的研究综述是对已发表文章的总结,为读者、研究人员和未来的作者提供了宝贵的资源。它追溯了喉气管-关节病-前突-身材矮小(LAPS)综合征的演变到现在的Myhre综合征。这些等位基因疾病是由SMAD4的致病变异引起的。在40多年前的首次报告之后,随着SMAD4致病变异的发现,病例报告和小系列的稳步出版加快了。这篇综述中的文章包括大量的病例报告和小系列,关于基础科学的报告,致病基因的发现,自然历史在大型研究中的出现,以及关于特定特征的文章,特别是心血管系统和气道。我们希望这一分析能为未来的研究提供基础,将基于症状的治疗扩展到基于基因的治疗。
{"title":"Research Review of Myhre Syndrome.","authors":"Maggie R Brand, Ryan Monsberger, Robert J Hopkin, Angela E Lin","doi":"10.1002/ajmg.c.32145","DOIUrl":"https://doi.org/10.1002/ajmg.c.32145","url":null,"abstract":"<p><p>This research review of Myhre syndrome is a summary of published articles which provide a valuable resource for readers, researchers, and future authors. It traces the evolution of the Laryngotracheal-Arthropathy-Prognathism-Short Stature (LAPS) syndrome to the current eponym of Myhre syndrome. These allelic disorders are caused by pathogenic variants in SMAD4. After the initial report over 40 years ago, the steady publication of case reports and small series was accelerated following the discovery of the pathogenic variants in SMAD4. The articles in this review include numerous case reports and small series, reports about basic science, the discovery of the causative gene, the emergence of the natural history in larger studies, and articles about specific features, especially the cardiovascular system and airways. We hope this analysis provides a foundation for future research that may extend symptom-based treatment to genetic-based therapy.</p>","PeriodicalId":7445,"journal":{"name":"American Journal of Medical Genetics Part C: Seminars in Medical Genetics","volume":" ","pages":"e32145"},"PeriodicalIF":2.8,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144232934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Visualizing Turner Syndrome 想象特纳综合症。
IF 4.4 3区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-06-02 DOI: 10.1002/ajmg.c.32144
Kirstine Stochholm, Astrid Bruun Rasmussen, Anne Skakkebæk

Turner syndrome (TS) continues to present a diagnostic challenge to healthcare professionals. The diagnostic challenges associated with TS result in delayed treatment and clinical care. Here we provide an update of the physical appearance of girls and women with TS by presenting clinical photographs and detailed clinical descriptions of 25 Danish girls and women with TS. Our data highlight the wide variation in physical appearance and clinical phenotype seen in girls and women with TS.

特纳综合征(TS)继续呈现诊断挑战医疗保健专业人员。与TS相关的诊断挑战导致延迟治疗和临床护理。在这里,我们通过提供25名丹麦女孩和妇女的临床照片和详细的临床描述,提供了患有TS的女孩和妇女的最新外表。我们的数据突出了患有TS的女孩和妇女在外表和临床表型上的广泛差异。
{"title":"Visualizing Turner Syndrome","authors":"Kirstine Stochholm,&nbsp;Astrid Bruun Rasmussen,&nbsp;Anne Skakkebæk","doi":"10.1002/ajmg.c.32144","DOIUrl":"10.1002/ajmg.c.32144","url":null,"abstract":"<p>Turner syndrome (TS) continues to present a diagnostic challenge to healthcare professionals. The diagnostic challenges associated with TS result in delayed treatment and clinical care. Here we provide an update of the physical appearance of girls and women with TS by presenting clinical photographs and detailed clinical descriptions of 25 Danish girls and women with TS. Our data highlight the wide variation in physical appearance and clinical phenotype seen in girls and women with TS.</p>","PeriodicalId":7445,"journal":{"name":"American Journal of Medical Genetics Part C: Seminars in Medical Genetics","volume":"199 2","pages":"134-138"},"PeriodicalIF":4.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajmg.c.32144","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144197992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Table of Contents, Volume 199, Number 1, March 2025 目录,第199卷,第1期,2025年3月
IF 2.8 3区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-05-21 DOI: 10.1002/ajmg.c.32091
{"title":"Table of Contents, Volume 199, Number 1, March 2025","authors":"","doi":"10.1002/ajmg.c.32091","DOIUrl":"https://doi.org/10.1002/ajmg.c.32091","url":null,"abstract":"","PeriodicalId":7445,"journal":{"name":"American Journal of Medical Genetics Part C: Seminars in Medical Genetics","volume":"199 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajmg.c.32091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144108978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cover Image, Volume 199, Number 1, March 2025 封面图片,第199卷,第1期,2025年3月
IF 2.8 3区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-05-21 DOI: 10.1002/ajmg.c.32143

From Stochholm et al. 2025. “Vizualizing Turner Syndrome.” American Journal of Medical Genetics Part C: Seminars in Medical Genetics: e32144. doi:10.1002/ajmg.c.32144. Photographs of individuals with Turner syndrome. Reproduced with permission from the patients and, where applicable, their legal guardians.

来自斯托霍姆等人,2025。“可视化特纳综合症。”美国医学遗传学杂志C部分:医学遗传学研讨会;e32144。doi: 10.1002 / ajmg.c.32144。特纳综合症患者的照片。经患者和(如适用)其法定监护人许可转载。
{"title":"Cover Image, Volume 199, Number 1, March 2025","authors":"","doi":"10.1002/ajmg.c.32143","DOIUrl":"https://doi.org/10.1002/ajmg.c.32143","url":null,"abstract":"<p>From Stochholm et al. 2025. “Vizualizing Turner Syndrome.” <i>American Journal of Medical Genetics Part C: Seminars in Medical Genetics</i>: e32144. doi:10.1002/ajmg.c.32144. Photographs of individuals with Turner syndrome. Reproduced with permission from the patients and, where applicable, their legal guardians.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":7445,"journal":{"name":"American Journal of Medical Genetics Part C: Seminars in Medical Genetics","volume":"199 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajmg.c.32143","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144108763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment From the Guest Editors 客座编辑的评论。
IF 2.8 3区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-04-30 DOI: 10.1002/ajmg.c.32141
Melissa L. Crenshaw, Anne Skakkebæk
{"title":"Comment From the Guest Editors","authors":"Melissa L. Crenshaw,&nbsp;Anne Skakkebæk","doi":"10.1002/ajmg.c.32141","DOIUrl":"10.1002/ajmg.c.32141","url":null,"abstract":"","PeriodicalId":7445,"journal":{"name":"American Journal of Medical Genetics Part C: Seminars in Medical Genetics","volume":"199 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parental Decision-Making Following a Prenatal Diagnosis of Turner Syndrome: A Systematic Review 特纳综合征产前诊断后的父母决策:系统回顾。
IF 4.4 3区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-04-08 DOI: 10.1002/ajmg.c.32140
Inger Lily Hjuler Dorf, Stina Lou, Anne Skakkebæk

This systematic review investigates factors influencing parental decision-making following a prenatal diagnosis (PND) of Turner syndrome (TS), aiming to enhance the foundation for tailored and supportive genetic counseling. A comprehensive literature search was conducted in the medical databases PubMed, Embase, and CINAHL. The selection of studies was guided by specific eligibility criteria. Extracted data was arranged in a review matrix, and study quality was assessed using a methodological quality score (MQS). Twenty-seven studies were selected for review, including 21 retrospective studies, five case reports, and one prospective study. The mean MQS across studies was 9.7 points (low to moderate). Across the included studies, nine categories of factors were investigated in association with parental decisions, including five pregnancy-related categories (ultrasound-detected abnormalities, karyotype, gestational age at diagnosis, time period of diagnosis, and prenatal counseling) and four categories related to expectant parents (age, reproductive history, expectations/concerns about the child's prognosis, and socio-demographic characteristics). Among these, ultrasound-detected abnormalities, karyotype, and counseling emerged as key factors influencing parental decisions. Parental decisions following a PND of TS are influenced by a complex interplay of medical, psychological, and socio-cultural factors. Addressing these determinants through patient-centered, non-directive counseling and equitable access to genetic expertise can support informed decision making.

本系统综述调查了特纳综合征(TS)产前诊断(PND)后影响父母决策的因素,旨在为量身定制和支持性遗传咨询奠定基础。在PubMed、Embase和CINAHL医学数据库中进行了全面的文献检索。研究的选择以特定的资格标准为指导。将提取的数据整理成回顾矩阵,并使用方法学质量评分(MQS)评估研究质量。选取27项研究进行综述,包括21项回顾性研究、5项病例报告和1项前瞻性研究。所有研究的平均MQS为9.7分(低到中等)。在纳入的研究中,研究人员调查了与父母决策相关的9类因素,包括5类与妊娠相关的因素(超声检测异常、核型、诊断时的胎龄、诊断时间和产前咨询)和4类与准父母相关的因素(年龄、生育史、对孩子预后的期望/担忧和社会人口特征)。其中,超声检测异常、核型和咨询成为影响父母决定的关键因素。父母在TS的PND后的决定受到医学、心理和社会文化因素的复杂相互作用的影响。通过以患者为中心的非指导性咨询和公平获得遗传专业知识来解决这些决定因素可以支持明智的决策。
{"title":"Parental Decision-Making Following a Prenatal Diagnosis of Turner Syndrome: A Systematic Review","authors":"Inger Lily Hjuler Dorf,&nbsp;Stina Lou,&nbsp;Anne Skakkebæk","doi":"10.1002/ajmg.c.32140","DOIUrl":"10.1002/ajmg.c.32140","url":null,"abstract":"<p>This systematic review investigates factors influencing parental decision-making following a prenatal diagnosis (PND) of Turner syndrome (TS), aiming to enhance the foundation for tailored and supportive genetic counseling. A comprehensive literature search was conducted in the medical databases PubMed, Embase, and CINAHL. The selection of studies was guided by specific eligibility criteria. Extracted data was arranged in a review matrix, and study quality was assessed using a methodological quality score (MQS). Twenty-seven studies were selected for review, including 21 retrospective studies, five case reports, and one prospective study. The mean MQS across studies was 9.7 points (low to moderate). Across the included studies, nine categories of factors were investigated in association with parental decisions, including five pregnancy-related categories (ultrasound-detected abnormalities, karyotype, gestational age at diagnosis, time period of diagnosis, and prenatal counseling) and four categories related to expectant parents (age, reproductive history, expectations/concerns about the child's prognosis, and socio-demographic characteristics). Among these, ultrasound-detected abnormalities, karyotype, and counseling emerged as key factors influencing parental decisions. Parental decisions following a PND of TS are influenced by a complex interplay of medical, psychological, and socio-cultural factors. Addressing these determinants through patient-centered, non-directive counseling and equitable access to genetic expertise can support informed decision making.</p>","PeriodicalId":7445,"journal":{"name":"American Journal of Medical Genetics Part C: Seminars in Medical Genetics","volume":"199 2","pages":"72-92"},"PeriodicalIF":4.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajmg.c.32140","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Cardiovascular Health Issues in Turner Syndrome: Expert Insights and Expanded Recommendations From the 2024 Guideline Development Team 特纳综合征心血管健康问题的管理:2024指南制定团队的专家见解和扩展建议
IF 4.4 3区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-03-26 DOI: 10.1002/ajmg.c.32139
Katya de Groote, Sheetal R. Patel, Kristian Havmand Mortensen, Isabel Witvrouwen, Anthonie Duijnhouwer, Nicole M. Brown, Jasmine Grewal, Kathryn C. Chatfield, Aaron T. Dorfman, Siddharth K. Prakash

Turner syndrome (TS) is frequently complicated by congenital heart disease (CHD). While left-sided lesions such as bicuspid aortic valve (BAV) and coarctation of the aorta are the most common structural heart lesions in TS, other anomalies, such as aortic arch malformations, hypoplastic left heart syndrome (HLHS), persistent left superior vena cava (LSVC), and partial anomalous pulmonary venous return (PAPVR), are also relatively frequent. Standardized mortality is increased threefold in individuals with TS compared to the general population, with cardiovascular complications, including aortic dissection, being the leading cause of death. The publication of the 2024 Clinical Practice Guidelines for TS marks an important opportunity to remind clinicians about the burden of congenital heart and vascular lesions in TS and the need for lifelong cardiovascular surveillance. In this expert panel statement, we will focus on the rationale for clinical management of CHD in TS, emphasizing TS-specific features of CHD that influence clinical decision making about therapeutic options and follow-up care.

特纳综合征(TS)常并发先天性心脏病(CHD)。虽然左侧病变如双尖瓣主动脉瓣(BAV)和主动脉缩窄是TS中最常见的结构性心脏病变,但其他异常,如主动脉弓畸形、左心发育不全综合征(HLHS)、持续性左上腔静脉(LSVC)和部分肺静脉异常回流(PAPVR)也相对常见。与一般人群相比,TS患者的标准化死亡率增加了三倍,心血管并发症,包括主动脉夹层,是死亡的主要原因。2024年TS临床实践指南的发布标志着一个重要的机会,提醒临床医生注意TS中先天性心脏和血管病变的负担以及终身心血管监测的必要性。在这份专家小组声明中,我们将重点讨论TS患者冠心病临床管理的基本原理,强调TS患者冠心病的特定特征会影响治疗方案和随访护理的临床决策。
{"title":"Management of Cardiovascular Health Issues in Turner Syndrome: Expert Insights and Expanded Recommendations From the 2024 Guideline Development Team","authors":"Katya de Groote,&nbsp;Sheetal R. Patel,&nbsp;Kristian Havmand Mortensen,&nbsp;Isabel Witvrouwen,&nbsp;Anthonie Duijnhouwer,&nbsp;Nicole M. Brown,&nbsp;Jasmine Grewal,&nbsp;Kathryn C. Chatfield,&nbsp;Aaron T. Dorfman,&nbsp;Siddharth K. Prakash","doi":"10.1002/ajmg.c.32139","DOIUrl":"10.1002/ajmg.c.32139","url":null,"abstract":"<p>Turner syndrome (TS) is frequently complicated by congenital heart disease (CHD). While left-sided lesions such as bicuspid aortic valve (BAV) and coarctation of the aorta are the most common structural heart lesions in TS, other anomalies, such as aortic arch malformations, hypoplastic left heart syndrome (HLHS), persistent left superior vena cava (LSVC), and partial anomalous pulmonary venous return (PAPVR), are also relatively frequent. Standardized mortality is increased threefold in individuals with TS compared to the general population, with cardiovascular complications, including aortic dissection, being the leading cause of death. The publication of the 2024 Clinical Practice Guidelines for TS marks an important opportunity to remind clinicians about the burden of congenital heart and vascular lesions in TS and the need for lifelong cardiovascular surveillance. In this expert panel statement, we will focus on the rationale for clinical management of CHD in TS, emphasizing TS-specific features of CHD that influence clinical decision making about therapeutic options and follow-up care.</p>","PeriodicalId":7445,"journal":{"name":"American Journal of Medical Genetics Part C: Seminars in Medical Genetics","volume":"199 2","pages":"51-71"},"PeriodicalIF":4.4,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajmg.c.32139","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-Invasive Prenatal Testing by Cell-Free DNA (cfNIPT) for Detecting Turner Syndrome With Mosaicism and Structural Variants—Prenatal Findings and Postnatal Outcomes 无细胞DNA (cfNIPT)无创产前检测特纳综合征与镶嵌和结构变异-产前发现和产后结果。
IF 4.4 3区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-03-05 DOI: 10.1002/ajmg.c.32136
Ivonne Bedei, Johanna Bruder, Ida C. B. Lund, Simon H. Thomsen, Ida Vogel, Andrea T. Maciel-Guerra, Francisco Alvarez-Nava, Melissa L. Crenshaw, Roland Axt-Fliedner, Claus H. Gravholt, Anne Skakkebæk

Turner Syndrome (TS) is a sex chromosomal disorder associated with karyotype heterogeneity. Although TS can be associated with severe prenatal findings, most often linked to the 45, X karyotype, the majority of TS fetuses have no overt phenotype, resulting in delayed diagnosis and management. The objective of this study is to assess the efficacy of non-invasive prenatal testing by cell-free DNA (cfNIPT) in detecting TS fetuses with different TS karyotype variants and to examine the phenotypic variations and clinical outcomes.Data on pregnancies with confirmed or suspected TS from 2000 to 2024 were collected from specialists in fetal ultrasound in Germany. In addition, a small number of Danish cases with 45, X mosaicism in the placenta was included. Data were collected regarding cfNIPT results, karyotypes, prenatal ultrasound findings, and pregnancy outcomes.Of the 114 cases included, 100 (87.7%) had a high-risk cfNIPT result for monosomy X, 53 (46.5%) were true positives (TP), and 47 (41.2%) were false positives (FP). Fourteen (12.3%) were false negatives (FN). No differences in congenital malformation or nuchal translucency were seen between TP and FN. Data on karyotype were available for 67 cases. Fourty (59.7%) had a 45, X karyotype, 16 (23.9%) 45, X mosaicism, and 11 (16.4%) had a structural variant. The 45, X karyotype was associated with a higher prevalence of congenital malformation and increased nuchal translucency (ps ≤ 0.001). The live birth rate was higher in cases with 45, X mosaicism or structural variants compared to cases with a 45, X karyotype (ps ≤ 0.03). Postnatal phenotypes were often mild.cfNIPT represents a valuable tool for the early identification of fetuses with TS karyotype variants, enabling timely intervention and targeted management. However, the high false-positive rate underscores the need for careful counseling.

特纳综合征(TS)是一种与核型异质性相关的性染色体疾病。虽然TS可能与严重的产前检查结果有关,最常与45x核型有关,但大多数TS胎儿没有明显的表型,导致诊断和治疗延迟。本研究的目的是评估无创产前无细胞DNA检测(cfNIPT)在检测具有不同TS核型变异的TS胎儿中的效果,并检查其表型变异和临床结果。从2000年到2024年,从德国胎儿超声专家那里收集了确诊或疑似TS的妊娠数据。此外,还包括少数丹麦病例,胎盘中有45,X嵌合现象。收集有关cfNIPT结果、核型、产前超声结果和妊娠结局的数据。114例患者中,100例(87.7%)为X单体cfNIPT高危结果,53例(46.5%)为真阳性(TP), 47例(41.2%)为假阳性(FP)。假阴性14例(12.3%)。TP和FN在先天性畸形和颈部半透明方面没有差异。对67例进行了核型分析。40例(59.7%)有45,X核型,16例(23.9%)有45,X嵌合,11例(16.4%)有结构变异。45x染色体核型与先天性畸形和颈部透明度增高相关(ps≤0.001)。与45,X染色体组相比,45,X染色体组的活产率更高(ps≤0.03)。出生后的表型通常是温和的。cfNIPT是早期识别TS核型变异胎儿的一种有价值的工具,能够及时干预和有针对性的管理。然而,高假阳性率强调了仔细咨询的必要性。
{"title":"Non-Invasive Prenatal Testing by Cell-Free DNA (cfNIPT) for Detecting Turner Syndrome With Mosaicism and Structural Variants—Prenatal Findings and Postnatal Outcomes","authors":"Ivonne Bedei,&nbsp;Johanna Bruder,&nbsp;Ida C. B. Lund,&nbsp;Simon H. Thomsen,&nbsp;Ida Vogel,&nbsp;Andrea T. Maciel-Guerra,&nbsp;Francisco Alvarez-Nava,&nbsp;Melissa L. Crenshaw,&nbsp;Roland Axt-Fliedner,&nbsp;Claus H. Gravholt,&nbsp;Anne Skakkebæk","doi":"10.1002/ajmg.c.32136","DOIUrl":"10.1002/ajmg.c.32136","url":null,"abstract":"<p>Turner Syndrome (TS) is a sex chromosomal disorder associated with karyotype heterogeneity. Although TS can be associated with severe prenatal findings, most often linked to the 45, X karyotype, the majority of TS fetuses have no overt phenotype, resulting in delayed diagnosis and management. The objective of this study is to assess the efficacy of non-invasive prenatal testing by cell-free DNA (cfNIPT) in detecting TS fetuses with different TS karyotype variants and to examine the phenotypic variations and clinical outcomes.Data on pregnancies with confirmed or suspected TS from 2000 to 2024 were collected from specialists in fetal ultrasound in Germany. In addition, a small number of Danish cases with 45, X mosaicism in the placenta was included. Data were collected regarding cfNIPT results, karyotypes, prenatal ultrasound findings, and pregnancy outcomes.Of the 114 cases included, 100 (87.7%) had a high-risk cfNIPT result for monosomy X, 53 (46.5%) were true positives (TP), and 47 (41.2%) were false positives (FP). Fourteen (12.3%) were false negatives (FN). No differences in congenital malformation or nuchal translucency were seen between TP and FN. Data on karyotype were available for 67 cases. Fourty (59.7%) had a 45, X karyotype, 16 (23.9%) 45, X mosaicism, and 11 (16.4%) had a structural variant. The 45, X karyotype was associated with a higher prevalence of congenital malformation and increased nuchal translucency (ps ≤ 0.001). The live birth rate was higher in cases with 45, X mosaicism or structural variants compared to cases with a 45, X karyotype (ps ≤ 0.03). Postnatal phenotypes were often mild.cfNIPT represents a valuable tool for the early identification of fetuses with TS karyotype variants, enabling timely intervention and targeted management. However, the high false-positive rate underscores the need for careful counseling.</p>","PeriodicalId":7445,"journal":{"name":"American Journal of Medical Genetics Part C: Seminars in Medical Genetics","volume":"199 2","pages":"124-133"},"PeriodicalIF":4.4,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajmg.c.32136","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growth and Growth-Promoting Treatments in Turner Syndrome 特纳综合征的生长与促生长治疗。
IF 2.8 3区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-02-14 DOI: 10.1002/ajmg.c.32133
Roopa Kanakatti Shankar, Charmian A. Quigley, Tsuyoshi Isojima, Nelly Mauras, Steven D. Chernausek, Malgorzata Wasniewska, Theo C. J. Sas

Short stature is a common presenting feature and an important concern for families of children with Turner syndrome. In this review, we summarize the data that shaped the updated international consensus guidelines for Turner syndrome published in 2024. The natural history of growth in Turner syndrome, the safety and efficacy of recombinant human growth hormone therapy, and the alternate growth promoting agents under consideration are presented. Timely, adequate growth hormone therapy can counter growth failure in childhood, promote catch-up growth and help many individuals with Turner syndrome attain a near-normal adult height. However, individual responses to growth hormone treatment are highly variable and are influenced by factors such as parental heights, age, baseline height, timing of estrogen initiation and pubertal status. Shared decision making on initiation of treatment, a candid conversation regarding the modest gradual height gain resulting from growth hormone therapy, and individualization of therapeutic goals can facilitate realistic expectations of growth promoting therapy in Turner syndrome.

身材矮小是特纳综合征儿童的常见表现,也是家庭关注的重要问题。在这篇综述中,我们总结了形成2024年发表的特纳综合征最新国际共识指南的数据。本文介绍了特纳综合征生长的自然历史,重组人生长激素治疗的安全性和有效性,以及正在考虑的替代生长促进剂。及时、适当的生长激素治疗可以对抗儿童时期的生长衰竭,促进追赶性生长,并帮助许多特纳综合征患者达到接近正常的成人身高。然而,个体对生长激素治疗的反应是高度可变的,并受到父母身高、年龄、基线身高、雌激素起始时间和青春期状态等因素的影响。共同决定开始治疗,就生长激素治疗导致的适度逐渐增加身高进行坦诚的对话,以及治疗目标的个性化,可以促进对特纳综合征生长促进治疗的现实期望。
{"title":"Growth and Growth-Promoting Treatments in Turner Syndrome","authors":"Roopa Kanakatti Shankar,&nbsp;Charmian A. Quigley,&nbsp;Tsuyoshi Isojima,&nbsp;Nelly Mauras,&nbsp;Steven D. Chernausek,&nbsp;Malgorzata Wasniewska,&nbsp;Theo C. J. Sas","doi":"10.1002/ajmg.c.32133","DOIUrl":"10.1002/ajmg.c.32133","url":null,"abstract":"<div>\u0000 \u0000 <p>Short stature is a common presenting feature and an important concern for families of children with Turner syndrome. In this review, we summarize the data that shaped the updated international consensus guidelines for Turner syndrome published in 2024. The natural history of growth in Turner syndrome, the safety and efficacy of recombinant human growth hormone therapy, and the alternate growth promoting agents under consideration are presented. Timely, adequate growth hormone therapy can counter growth failure in childhood, promote catch-up growth and help many individuals with Turner syndrome attain a near-normal adult height. However, individual responses to growth hormone treatment are highly variable and are influenced by factors such as parental heights, age, baseline height, timing of estrogen initiation and pubertal status. Shared decision making on initiation of treatment, a candid conversation regarding the modest gradual height gain resulting from growth hormone therapy, and individualization of therapeutic goals can facilitate realistic expectations of growth promoting therapy in Turner syndrome.</p>\u0000 </div>","PeriodicalId":7445,"journal":{"name":"American Journal of Medical Genetics Part C: Seminars in Medical Genetics","volume":"199 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American Journal of Medical Genetics Part C: Seminars in Medical Genetics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1